Product Pipeline
With medications in more than 4 therapeutic areas and over 15 products in just 5 years, Xeedia established itself as an industry leader. We’re dedicated to bringing the newest and most effective solutions and are always researching to create better and bigger ones.
The following table lists a selection of our product pipeline for the year
You-Q10 400mg
Supplement
Active
coenzyme Q10400Mg
Potential Indication
Status
Supports Fertility & Body Energy
Under Development
Business unit line
General Health
Therapeutic Area
General Health
Dosage form
Soft Gelatin Capsules
Potential Indication
Status
Expected launch month
Supports Fertility & Body Energy
Under Development
Feb 2027
Omegal VIT
Supplement
Active
Fish oil500mgContaining:Omega3freefattyacid300Mg(54%-66%)EicosapentanoicAcidEPA(9%–11%)50mgDocosahexanoicAcidDHA(45%-55%)250mgAscorbicacid(vitaminc)60mgD-LTocopherylacetate13.33Mgeq.tovitaminE6mgNiacin(vitaminb3)8mgZinccitrate7.32mgeq.tozinc2.5mgCalciumD-pantothenate3.2608mgeq.tovitaminb53mgRiboflavinsodiumphosphate0.8895eq.to0.7mgPyridoxineHydrochloride0.8508mgeq.tovitaminb60.7mgThiaminehydrochloride0.7mgeq.tovitaminb10.55mgCholecalciferoloil400μg1MIU/Igmeq.tovitaminD3400iuRetinylPalmitate[1.7MIU/g]392.157μgeq.tovitaminA200μgPotassiumiodide52.324μgEQ.TO40μgIodineSodiumselenate35.893μgeq.toselenium15μgBiotin12.5μg
Potential Indication
Status
Supports Normal Brain Function
Under Development
Business unit line
General Health
Therapeutic Area
Child Care
Dosage form
Oral Suspension
Potential Indication
Status
Expected launch month
Supports Normal Brain Function
Under Development
Jan 2027
Omegal Kids
Supplement
Active
Fish oil providing2100mgEicosapentanoicAcidEPA(16.5%–19.8%)378mgDocosahexanoicAcidDHA(10.8%-13.2%)252mgD-LAlpha-tocopherylacetate28.889mgeq.to13mgMenaquinone-71100µg[5%]oileqtovitaminK255µgRetinolPalmitate470.588µg[1.7MIU/gm]EQ.TOVitaminA800IUCholecalciferol400µg[1MIU/1gm]oilEQ.TOVITAMIND3400IU
Potential Indication
Status
Maintains Normal Brain Function
Under Development
Business unit line
General Health
Therapeutic Area
Child Care
Dosage form
Oral Syrup
Potential Indication
Status
Expected launch month
Maintains Normal Brain Function
Under Development
Jan 2027
You-Mag
Supplement
Active
Magnesium Citrate385mgeqtoMagnesium62.23mgMagnesiumoxide311.37mgeqtoMagnesium187.77mg
Potential Indication
Status
Contributes to the Reduction of Fatigue & Supports Nervous System and Muscle Function
Under Development
Business unit line
General Health
Therapeutic Area
General Health
Dosage form
Soft Gelatin Capsules
Potential Indication
Status
Expected launch month
Contributes to the Reduction of Fatigue & Supports Nervous System and Muscle Function
Under Development
Feb 2027
You-Q10 200mg
Supplement
Active
coenzyme Q10200Mg
Potential Indication
Status
Supports Fertility & Body Energy
Under Development
Business unit line
General Health
Therapeutic Area
General Health
Dosage form
Soft Gelatin Capsules
Potential Indication
Status
Expected launch month
Supports Fertility & Body Energy
Under Development
Feb 2027
Omegal Mini
Supplement
Active
Tuna Fish Oil containing :400mgDHA(22.5%-27.5%)100mgCholecalciferolconcentrate(oilform)VitaminD3min1.0MIU/g0.4mgeqtoVitaminD310mcgDLtocopherylacetate5mgeqtovitaminE5IU
Potential Indication
Status
Supports Healthy Growth & Development
Under Development
Business unit line
General Health
Therapeutic Area
Child Care
Dosage form
Oral Liquid Drops
Potential Indication
Status
Expected launch month
Supports Healthy Growth & Development
Under Development
Apr 2027
Diclopro spray
Pharmaceutical
Active
diclofenac sodium4%
Potential Indication
Status
sprains - strains - low back pain - RA- OA
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
cutaneous spray solution
Potential Indication
Status
Expected launch month
sprains - strains - low back pain - RA- OA
Under Development
Feb 2025
Diclopro Relax
Pharmaceutical
Active
methocarbamol500MG
diclofenac50MG
Potential Indication
Status
Muscle relaxant - Muscle spasm
Under Development
Business unit line
orthopedic
Therapeutic Area
MUSCLE RELAXANTS, CENTRAL
Dosage form
Film coated tablet
Potential Indication
Status
Expected launch month
Muscle relaxant - Muscle spasm
Under Development
Jul 2025
Diclopro syp
Pharmaceutical
Active
diclofenac potassium2mg/ml
Potential Indication
Status
anti inflammatory - antipyretic - analgesic
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
Suspention
Potential Indication
Status
Expected launch month
anti inflammatory - antipyretic - analgesic
Under Development
Jul 2025
Diclopro Amp
Pharmaceutical
Active
diclofenac sodium75MG/3ML
Potential Indication
Status
osteoarthritis - RA -Arthritis flare ups - Gout- Acute musculoskeletal disorders
Under Development
Business unit line
orthopedic
Therapeutic Area
ANTIRHEUMATICS NON-S PLN
Dosage form
solution for IM injection or IV infusion
Potential Indication
Status
Expected launch month
osteoarthritis - RA -Arthritis flare ups - Gout- Acute musculoskeletal disorders
Under Development
Sep 2025
Osvyrti
Pharmaceutical
Active
Denosumab60mg/ml
Potential Indication
Status
Osteoprosis
Under Development
Business unit line
Orthopedic & Rheumatology
Therapeutic Area
Endocrinolgy/Metabolic Bone Diseases and Oncology/Supportive Cancer Care
Dosage form
Solution for Injection
Potential Indication
Status
Expected launch month
Osteoprosis
Under Development
Oct 2027
Linagliflozin Met 10/5/1000mg
Pharmaceutical
Active
Empagliflozin10mgLinagliptin5mgMetformin1000mg
Potential Indication
Status
Type 2 Diabetes
Under Development
Business unit line
Cardiovascular Metabolic
Therapeutic Area
Endocrinology and Metabolic Diseases
Dosage form
Extended Release Film Coated Tablets
Potential Indication
Status
Expected launch month
Type 2 Diabetes
Under Development
Jul 2027
Linagliflozin Met 25/5/1000mg
Pharmaceutical
Active
EMPAGLIFLOZIN25mgLinagliptin5mgMETFORMINHYDROCHLORIDE1000mg
Potential Indication
Status
Type 2 Diabetes
Under Development
Business unit line
Cardiovascular Metabolic
Therapeutic Area
Endocrinology and Metabolic Diseases
Dosage form
Extended Release Film Coated Tablet
Potential Indication
Status
Expected launch month
Type 2 Diabetes
Under Development
Jul 2027
Linagliflozin Met 12.5/2.5/1000 MG
Pharmaceutical
Active
Empagliflozin12.5mgLinagliflozin2.5mgMetforminHydrochloride1000mg
Potential Indication
Status
Type 2 Diabetes
Under Development
Business unit line
Cardiovascular Metabolic
Therapeutic Area
Endocrinolgy & Metabolic Diseases
Dosage form
Extended Release Film Coated Tablets
Potential Indication
Status
Expected launch month
Type 2 Diabetes
Under Development
Jul 2027
Sondelbay
Pharmaceutical
Active
Teriparatide0.25mg/ml
Potential Indication
Status
Osteoprosis
Under Development
Business unit line
Oncolgy
Therapeutic Area
Endocrinology and Bone Metabolism
Dosage form
Solution for Injection
Potential Indication
Status
Expected launch month
Osteoprosis
Under Development
Oct 2027
Jubereq
Pharmaceutical
Active
Denosumab120mg/1.7ml
Potential Indication
Status
Bone Metastases & Multiple Myeloma
Under Development
Business unit line
Oncology
Therapeutic Area
Endocrinology/Metabolic Bone Diseases and Oncology/Supportive Cancer Care
Dosage form
Solution for Injection
Potential Indication
Status
Expected launch month
Bone Metastases & Multiple Myeloma
Under Development
Oct 2027
Newsletter